HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Vol 21, No 11, November 2017 – Paediatric Illnesses       » Breakthrough new rice variety announced in Northern China       » Ebola vaccine approved in China       » Study reveals anti-cancer properties of a fungus used in traditional medicine       » Chinese scientists create genetically modified low-fat pigs       » China, Brazil and Russia are riskiest markets for compliance and regulation       » Why are Korean eggs salmonella-free?      
INSIDE INDUSTRY
Phosphagenics licenses TPM® platform to Indian pharmaceutical company
Australian drug delivery technology company Phosphagenics Limited has licensed an injectable antibiotic product, harnessing its proprietary TPM® platform technology, to Agila Specialties Private Limited (Agila). Agila is a wholly owned subsidiary of the listed Indian pharmaceutical company, Strides Arcolab (Strides).

Agila has one of the largest steriles capacities in India and amongst the largest lyophilization (freeze drying) capacities in the world with its operations spread over nine world-class manufacturing facilities around the globe. The company is focused on developing and commercializing new products for key therapeutic markets targeting antiinfectives, oncology, central nervous system (CNS), gastro-intestinal (GI), ophthalmics and peptides.

Under the terms of the exclusive global license agreement, Phosphagenics will license the TPM® technology to Agila for its use in an antibiotic injectable product. Agila will be responsible for the development and pay the costs required to register and commercialize the product including all necessary clinical studies.

Phosphagenics will receive an upfront payment as well as undisclosed royalties based on net sales. The size of the antibiotic injectables market is several billion dollars annually.

Company CEO, Dr Esra Ogru, said this agreement demonstrates the versatility of the TPM® platform technology, paving the way for further opportunities in the injectable market.

 “Strides and its subsidiary, Agila, have state-of-the-art manufacturing capabilities and have had tremendous success in bringing new products to market. This will be the first time TPM® will be used in an injectable formulation.”

Click here for the complete issue.

NEWS CRUNCH  
news MIT Technology Review announces 2018's 10 'Innovators Under 35 Asia'
news Novogen becomes Kazia Therapeutics
news Transforming healthcare through innovation: addressing unmet healthcare needs in Asia Pacific
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Lady Ganga: Nilza'S Story
COLUMNS  
Subscribe to APBN E-Newsletter
Find us under 'Others' option to receive APBN e-newsletters thrice a month!

APBN Editorial Calendar 2017
January:
Healthcare Focus: LUNGS
February:
War on CANCER
March:
Get to Know TCM
April:
Diabetes: The Big Picture
May:
The Piece of Your Mind - Brain Health/Science
June:
Advocacies in Support of Rare Disease Patients
July:
Food Science & Technology
August:
Eye – the Window to your Soul
September:
Infectious Diseases
October:
A change of heart — Cardiovascular diseases
November:
Paediatric Illnesses
December:
Skin Diseases/Allergic Reactions
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Lim Guan Yu
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2017 World Scientific Publishing Co Pte Ltd  •  Privacy Policy